BioAge Signs Exclusive Agreement With Amgen To Develop and Commercialize Amgen’s Phase 1 APJ Agonist To Treat Diseases of Aging
\xe2\x80\x9cUsing this robust approach, we found that higher levels of apelin signalling in older people are associated with increased lifespan and reduced symptoms of frailty.
- \xe2\x80\x9cUsing this robust approach, we found that higher levels of apelin signalling in older people are associated with increased lifespan and reduced symptoms of frailty.
- Our human-first analysis suggests that the apelin-mimicking drug BGE-105 could recapitulate these positive effects in older patients.\xe2\x80\x9d\nIn mice, deficiency in apelin or APJ accelerates loss of muscle function.
- By targeting the mechanisms of aging with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent these diseases in entirely new ways.
- For additional information about BioAge, visit the company\xe2\x80\x99s website at www.bioagelabs.com .\n'